HFA 134a (hydrofluoroalkane)

Subscribe to Selected New Research on HFA 134a

107 relevant articles (13 outcomes, 30 trials/studies) found for this Bio-Agent

Also Known As:

hydrofluoroalkane; 1,1,1,2,3,3,3-heptafluoropropane; 2H-heptafluoropropane; HFA 227; HFA-134a; HFA-227; hydrofluoroalkane-134a

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 40

Hydrocarbons: 382

Halogenated Hydrocarbons: 28

Fluorinated Hydrocarbons: 2

HFA 134a: 107

Experts

1.	Dorinsky, Paul: 3 articles (01/2006 - 09/2003)
2.	Scott, Catherine: 3 articles (01/2006 - 09/2003)
3.	Donnell, D: 3 articles (08/2004 - 12/2000)
4.	Wilson, A M: 2 articles (10/2008 - 10/2002)
5.	Ohbayashi, Hiroyuki: 2 articles (09/2008 - 01/2007)
6.	Mehta, Rashmi: 2 articles (01/2008 - 11/2006)
7.	Scott, Catherine A: 2 articles (11/2006 - 12/2005)
8.	Crim, Courtney: 2 articles (11/2006 - 12/2005)
9.	Wu, Wei: 2 articles (11/2006 - 12/2005)
10.	House, Karen: 2 articles (01/2006 - 01/2004)

Related Diseases

1.	Asthma (Bronchial Asthma) 01/01/2006 - "CONCLUSIONS: In these adolescent and adult patients whose asthma was not controlled by medium doses of an ICS, FSC delivered via HFA 134a MDI (2 inhalations of 110/21-microg strength administered BID) was more effective in improving lung function than FP or SAL monotherapy or PLA" 06/01/2000 - "The study period was 12 months and involved 412 subjects with moderate to severe asthma (HFA 134a pMDI: n = 203; CFC pMDI: n = 209)" 07/01/2007 - "CONCLUSIONS: BID doses of SFC hydrofluoroalkane 50/100 pg, 50/250 pg, and 50/500 pg administered via MDI for 52 weeks were well tolerated in this population of adolescents and adults with persistent asthma." 03/01/2007 - "CONCLUSION: MF delivered by HFA-227 MDI significantly reduces daily OCS use compared with placebo and facilitates elimination of OCS use in patients with severe persistent asthma." 01/01/2007 - "Most significant are the choice of hydrofluoroalkane-134a (HFA-134a) as a new propellant (rather than chlorofluorocarbon, CFC), a smaller exit nozzle diameter and attachment of a spacer in order to reduce ultimately droplet size and spray inhalation speed, both contributing to higher deposition efficiencies and hence better asthma therapy" Get all the results and reference details, order at left...
2.	Chronic Obstructive Pulmonary Disease (COPD) 10/01/2001 - "Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD." 10/01/2001 - "STUDY OBJECTIVE: To compare the efficacy and safety of ipratropium bromide reformulated with the chlorofluorocarbon (CFC)-free propellant hydrofluoroalkane (HFA)-134a (ipratropium bromide HFA) to that of the marketed ipratropium bromide inhalation aerosol (containing CFC) in patients with COPD" 11/01/2006 - "In an open-label study at 37 outpatient centers, patients > or =4 years old with asthma or chronic obstructive pulmonary disease requiring short-acting 32-agonists received two actuations of albuterol hydrofluoroalkane (HFA) [Ventolin HFA: GlaxoSmithKline], 90 microg twice daily, via a novel MDI with an integrated dose counter until all 200 actuations were completed" 01/01/2008 - "OBJECTIVES: The aim of this study was to assess the effectiveness of an extra-fine ICS, hydrofluoroalkane-134a beclometasone dipropionate (HFA-BDP) with a mass median aerodynamic diameter of 1.1 microm, on lung function and exercise tolerance in COPD patients with AATD when added to long-acting bronchodilators (LABAs)" 05/01/2003 - "METHODS: Forty-one stable patients with moderate COPD (FEV(1) approximately 60% predicted) were randomized to sequence 1; first HFA-134a beclomethasone dipropionate (HFA-BDP, an ICS with more peripheral deposition) 400 microg b.i.d., then fluticasone propionate (FP, an ICS with more central deposition) 375 microg b.i.d" Get all the results and reference details, order at left...
3.	Inflammation 12/01/2002 - "The new hydrofluoroalkane preparations offer more lung deposition and may be important in treating inflammation of the small airways in patients with asthma." 05/01/2007 - "CONCLUSIONS: Delivering hydrofluoroalkane beclomethasone dipropionate via the NH and AP attenuates asthmatic airway inflammation to a comparable degree and produces a similar in vitro fine particle dose profile." 01/01/2007 - "One-year evaluation of the preventative effect of hydrofluoroalkane-beclomethasone dipropionate on eosinophilic inflammation of asthmatic peripheral airways." 06/01/2008 - "Therefore, extra-fine hydrofluoroalkane-beclomethasone may be particularly useful for treating peripheral airway inflammation in asthma" 01/01/2007 - "OBJECTIVE: It was the aim of this study to assess persistent eosinophilic inflammation of the peripheral airways in asthmatic patients, stabilized by the long-term use of dry powder type inhaled steroids, and to evaluate the clinical efficacy of hydrofluoroalkane-beclomethasone dipropionate (HFA-BDP) over 1 year" Get all the results and reference details, order at left...
4.	Obstructive Lung Diseases (Obstructive Lung Disease) 01/01/2005 - "We report a study that specifically assessed inhaler preference in patients with obstructive lung disease after treatment with ipratropium bromide/fenoterol hydrobromide (Berodual delivered via either Respimat Soft Mist Inhaler (SMI) or hydrofluoroalkane metered dose inhaler (HFA-MDI)" Get all the results and reference details, order at left...
5.	Infection 05/01/2006 - "OBJECTIVE: The aim of this study was to estimate whether switching to an equal daily dose of inhaled hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP), the oropharyngeal deposition of which is very low, can eliminate the infection without deterioration of asthma" Get all the results and reference details, order at left...
14 Diseases and 107 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Beclomethasone (Beclometasone)
2.	HFA 134a (hydrofluoroalkane)
3.	fluticasone (Cutivate)
4.	Albuterol (Salbutamol)
5.	Budesonide (Pulmicort)
6.	Ipratropium (Ipratropium Bromide)
7.	ciclesonide
8.	formoterol (Oxis)
9.	(3,4-dihydroxyphenylamino)-2-imidazoline (DPI)
10.	Steroids
35 Drugs and Important Bio-Agents and 97 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Metered Dose Inhalers (Metered Dose Inhaler)
2.	Nebulizers and Vaporizers (Inhaler)
3.	Aftercare (After-Treatment)
3 Therapies and Procedures and 35 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>